ALSO ON THIS PAGE:   Comparison Chart   |   About PEPID LLC


PEPID and the Goliaths

Chicago-based firm beats larger competitors with No. 1 PDA drug database rating

SKOKIE, IL, November 1, 2005 - PEPID’s Portable Drug Companion (PDC) database is ranked number one for healthcare practitioners in a recent independent study. PEPID PDC beat ten other contenders in this independent benchmark study of practical PDA prescribing solutions for doctors and nurses.

The drug information product from PEPID—a relatively small, privately held pioneer in the field—out ranked databases from medical publishing behemoths like Connecticut-based The Thompson Corporation ($8.1 billion in revenues in 2004) and Amsterdam’s Wolters Kluwer (about $4 billion in annual revenues). With giants like GE, Microsoft, and Kaiser Permanente looking to invade the space, the stakes are high.

Medical information experts estimate that providing healthcare professionals with PDA-based, point-of-care medical and drug information is potentially a $3 to $5 billion a year market in the U. S. alone. Checking drugs and drug interactions is the number one reason healthcare professionals consult their PDAs. The quality of the drug database is often the leading criterion for doctors and nurses when they choose a PDA resource.

“To many practitioners, the drug database is the backbone of their point-of-care information resource,” says Dr. Mark Rosenbloom, PEPID Founder and CEO. “To achieve a top ranking in this area is a tribute to the ingenuity and focus that a company, like ours, can devote to developing the highest quality, most innovative resources in the marketplace.”

A pioneer in its field, PEPID is the only software developer to fully-integrate its drug database into complete clinical information resources that include diagnostic information, treatment recommendations, dosing calculators, and much more. PEPID offers discipline-specific software solutions for physicians, nurses, students, paramedics and pharmacists.

In the study, led by Georgetown University Medical Center’s Dr. Björn Knollmann, PhD, PEPID PDC scored highest on a combination of the features that mean the most to clinical practitioners including structured information on indications and dosing, side effects, drug interactions, and ‘special features’ like medical calculators and treatment algorithms. The study also noted PEPID was the only product that provided information on the compatibility of various intravenous solutions.

Today, a majority of physicians use PDAs as a point-of-care, decision-making resource. Seventy-two percent of these physicians consult their handheld devices for drug related information. The study, Personal digital assistant-based drug reference software as tools to improve traditional prescribing: Benchmark criteria and performance, Knollmann et al, was supported by the National Institute of Health and issued from the Division of Clinical Pharmacology and Center for Drug Development Sciences, Georgetown University Medical Center.

PDA Drug Software Ranking
© 2005 by the American Society for Clinical Pharmacology and Therapeutics


Fig 1 . Comparison of rational prescribing features. The following categories from Table I are included in the score for rational prescribing features: structured information on indications and dosing (0–6 points), side effects (0–4 points), drug interactions (0–4 points), and special features (0–8 points).

 

About PEPID and PEPID PDC

PEPID, LLC was founded in 1994 by Dr. Mark Rosenbloom, a board-certified emergency physician and faculty member at Northwestern University’s Feinberg School of Medicine in Chicago. There are PEPID products designed for physicians, nurses, students, paramedics and pharmacists. By making their mobile workplace more efficient and productive, PEPID medical information resources result in greater career satisfaction for healthcare professionals. At point-of-care, they provide current pharmacological and clinical information via handheld computers and the Internet. PEPID PDC is available as a stand alone product and is continually updated. More information about PEPID products can be found at www.pepid.com

 

PEPID™, product names and logotypes are trade marks of PEPID LLC.
The article is copyright © 2005 by the American Society for Clinical Pharmacology and Therapeutics. Other product and corporate names may be registered trade marks of their respective owners.

Copyright © 2000-2005. All rights reserved.